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 COPD is a major public health issue, 1 but recent national survey data revealed that 50% of cases 
are not diagnosed. 2 Spirometry is the accepted stan-
dard for the diagnosis and classifi cation of severity for 
COPD, 3 but it is underused by most health-care 
practitioners. 4-10 The US Preventive Services Task 
Force (USPSTF) recently recommended against 
spirometric testing for COPD in the absence of 
symptoms, despite an admission that respiratory 
symptom status is not a reliable indicator of the pres-
ence of airways obstruction (AO). 11 However, the 
USPSTF further stated that spirometry may be ben-
efi cial in symptomatic adults who have an FEV 1 
 . 60% predicted for determining when to initiate 
therapy. 
 In this study, respiratory symptoms and spiromet-
ric data from a large cohort were evaluated to deter-
mine whether COPD is underdiagnosed and to 
 Background:  The US Preventive Services Task Force recommends against spirometry in the 
absence of symptoms. However, as much as 50% of COPD cases in the United States remain 
undiagnosed. 
 Methods:  Report of symptoms, smoking history, and spirometric data were collected from subjects 
screened for a work-related medical evaluation (N  5 3,955). Prevalence of airfl ow obstruction and 
respiratory symptoms were assessed. Sensitivity, specifi city, positive and negative predictive values, 
and relative risks of predicting symptoms and smoking history for COPD were calculated. 
 Results:  Forty-four percent of smokers in our sample had airways obstruction (AO). Of these, 36% 
reported a diagnosis of or treatment for COPD. Odds ratio (95% CI) for AO with smoking 
(  20 pack-years) was 3.73 (3.12- 4.45), 1.98 (1.73-2.27) for cough, 1.79 (1.55-2.08) for dyspnea, 
1.95 (1.70-2.34) for sputum, and 2.59 (2.26-2.97) for wheeze. Respiratory symptoms were reported 
by 92% of smokers with AO, 86% smokers with restriction, 76% smokers with normal spirometry, 
and 73% of nonsmokers. Sensitivity (92% vs 90%), specifi city (19% vs 22%), positive (47% vs 40%) 
and negative (75% vs 80%) predictive values for the presence of one or more symptoms were 
similar between smokers and all subjects. 
 Conclusions:  COPD is underdiagnosed in the United States. Symptoms are frequent in subjects 
with AO and increase their risk for COPD, but add little beyond age and smoking history to the 
predictive value of spirometry. In view of the high prevalence of symptoms and their poor predic-
tive value, a simpler and more effective approach would be to screen older smokers. 
 CHEST 2010; 137(6):1345–1353 
 Abbreviations:  AO  5 airways obstruction; GOLD  5 Global Initiative for Chronic Obstructive Lung Disease; LLN  5 lower 
limit of normal; NHANES  5 National Health and Nutrition Examination Survey; OR  5 odds ratio; RR  5 relative risk; 
USPSTF  5 US Preventive Services Task Force 
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graph was read by a certifi ed B reader according to International 
Labor Organization standards to exclude subjects with signifi cant 
pneumoconiosis. 13 This protocol was reviewed and approved by 
the Saint Louis University and Wake Forest University institu-
tional review boards. 
 Pulmonary Function Testing 
 Pulmonary function testing was performed according to 
American Thoracic Society guidelines. 14,15 Spirometric data 
were expressed as percent predicted using National Health and 
Nutrition Examination Survey (NHANES) standards. 15,16 COPD 
was defi ned in accordance with Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines, 17 using a fi xed 
FEV 1 /FVC ratio  , 70% in long-term smokers aged   40 years. 
Long-term smoking was defi ned as   20 pack-years. Never-
smokers or those who smoked  , 20 pack-years were considered 
nonsmokers. Severity of airway obstruction was quantifi ed in 
accordance with GOLD guidelines. 17 The fi xed FEV 1 /FVC ratio 
is known to underestimate the presence of obstruction in young 
patients and to overestimate it in older patients 16,18-21 ; therefore, 
a secondary analysis of the data using the lower limit of normal 
(LLN) defi nition for obstruction based on NHANES standards 
was performed. 22,23 
 Subject Groups and Variables Measured 
 Smokers were divided into three groups based on spirometry: 
subjects with COPD (FEV 1 /FVC,  , 70%) (n  5 1,269), unaffected 
smokers with normal spirometry (FEV 1 / FVC,   70%; percent-
predicted FVC,  . 80%) (n  5 792), and restricted smokers (FEV 1 / 
FVC,   70%; percent-predicted FVC,   80%) (n  5 856). Exclusion 
answer three questions: (1) Is there an association of 
symptoms with the presence of AO? (2) If there is 
such an association, are symptoms sensitive and spe-
cifi c for the presence of AO? (3) Does the absence 
of symptoms exclude AO (ie, is there underdiagnosis 
of COPD if only symptomatic smokers are tested)? 
We confi rm that COPD is underdiagnosed and that 
most patients with AO are symptomatic. Symptoms 
increase the risk for COPD but add little beyond age 
and smoking history to positive predictive value of 
spirometry. 
 Materials and Methods 
 Study Population 
 Subjects were recruited from a cohort referred for a work-
related medical evaluation from 1980 to 2008 that included a ques-
tionnaire, chest radiographs, and pulmonary function tests. The 
cohort originally was described in 2004. 12 Referrals were drawn 
from trade unions and television and newspaper advertisements. 
Cigarette smoking was quantifi ed by pack-years. Subjects were 
queried about the presence and duration of symptoms, such as 
cough, sputum, dyspnea on exertion, and wheeze, on most days of 
the week for   1 year and asked to list all current medications. 
They were asked whether and when they had received a diagnosis 
from a health-care professional of asthma, COPD, chronic 
bronchitis, or emphysema. All responses were verifi ed by the 
physician-examiner during face-to-face interviews. A chest radio-
 Table 1— Subject Demographics Using Fixed Ratio To Defi ne Airway Obstruction 
Demographic Total
Nonsmokers or 
 , 20 Pack-y Smokers









No. subjects 3,955 1,038 744 525 856 792
Age, y 64.1  6 9.6 63.2  6 10.2 65.7  6 8.9 67.2  6 8.6 64.0  6 9.4 61.9  6 9.5
FEV 1 , % predicted 74.9  6 20.6 84.5  6 17.4 65.3  6 16.3 48.4  6 18.4 71.0  6 11.6 93.2  6 8.9
Pack-y 39.4  6 31.7 4.6  6 6.4 53.4  6 27.0 59.8  6 30.1 51.2  6 27.4 45.5  6 25.4
BMI 29.2  6 4.8 29.9  6 4.9 27.8  6 4.5 27.8  6 5.0 30.4  6 4.9 29.1  6 4.2
Data are presented as mean  6 SD. COPD is defi ned as FEV 1 /FVC  , 70% (aged   40 years and   20 pack-years of smoking). Unaffected smokers 
are defi ned as having a normal spirometry of FEV 1 /FVC   70% and percent-predicted FVC  . 80% (aged   40 years and   20 pack-years of 
smoking). Restricted smokers are defi ned as having an FEV 1 /FVC   70% and percent-predicted FVC   80% (aged   40 years and   20 pack-years 
of smoking).
 Table 2— Frequency of Symptoms a Using Fixed Ratio To Defi ne Obstruction 
Symptom Total
Nonsmokers or 
 , 20-Pack-y Smokers









Cough 58.3 46.1 78.4 65.4 60.5 51.8
Sputum 46.6 46.0 63.7 51.6 40.9 36.9
Wheeze 53.5 38.5 84.3 59.1 58.2 42.4
Dyspnea 67.6 63.1 90.1 66.9 70.8 55.5
No symptom 17.6 27.2 2.5 11.8 14.0 24.2
No. of symptoms, 
 mean  6 SD
2.1  6 1.4 1.7  6 1.4 3.1  6 1.1 2.4  6 1.4 2.3  6 1.4 1.8  6 1.4
 a Percentage of subjects experiencing symptoms.
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 For wheeze and shortness of breath, the RR was calculated. 
Because cough showed a signifi cant interaction ( P  , .1) with both 
age and pack-years, the next step in calculation of RRs was based 
on the presence or absence of cough. Because having sputum 
depends on having cough, the RRs for sputum is offered only 
when cough is present. Based on the presence or absence of 
cough, the RR for the difference in age and the difference in 
pack-years smoked was calculated. 
 We used a  t test to evaluate the signifi cance of differences 
between groups for continuous variables. Statistical analysis was 
performed using SAS version 9.1 (SAS Institute; Cary, NC). Val-
ues are expressed as mean  6 SD. 
 Results 
 Study Population Demographics 
 Smokers with obstruction were older, smoked 
more, and experienced more symptoms than smokers 
with restrictive or normal spirometry ( P  , .001) 
( Tables 1, 2) . Few smokers had a remote history of 
lung cancer ( Fig 1 ). In the 1,269 subjects with 
obstructed spirometry, 86% were GOLD stages II to 
IV. BMI was signifi cantly greater in restricted smok-
ers compared with all other smoking groups and 
lower in smokers with obstruction compared with 
smokers with normal spirometry ( P  , .05) ( Table 1 ). 
Only fi xed-ratio comparisons are presented because 
there were marginal differences in results between 
these and LLN. 
 Prevalence of Respiratory Symptoms, 
AO, and COPD 
 Symptoms were present in 92% of the smokers 
with obstruction and were linearly related ( P  , .001) 
to pack-years smoked and FEV 1 ( Tables 3, 4 ). Symp-
toms also were present in 76% of smokers with nor-
mal and 86% of smokers with restricted spirometry. 
Most of the asymptomatic smokers with obstruction 
had GOLD stage II COPD (62%), and 10% had 
GOLD stage III or IV COPD. 
 There was a 17% prevalence of obstruction in sub-
jects who never smoked (n  5 178) or smoked  , 20 
pack-years (n  5 1,038). Of these subjects, 79% had 
symptoms. The mean FEV 1 for the nonsmokers with 
obstruction was 66.6  6 18.2%, and their average age 
was 68.2  6 9.7 years. Of the 178 nonsmokers 
criteria were radiographic evidence of signifi cant pneumoconiosis, 
the presence of mesothelioma, active lung cancer, and any disor-
der with an expected survival of  , 1 year. Study variables evalu-
ated were age; pack-years smoked; and the presence of cough, 
sputum, wheeze, and dyspnea. A physician diagnosis of asthma, 
chronic bronchitis, emphysema, and COPD was based on patient 
report. 
 Statistical Analysis 
 Sensitivity, specifi city, and negative and positive predictive val-
ues of variables for the presence of obstruction were calculated. 
Logistic regression was used to estimate the odds ratios (OR) of 
both individual and combinations of respiratory symptoms, age, 
and smoking history of   20 pack-years for AO. To do so, we satu-
rated the model with all the variables and their two-way interac-
tions. We next eliminated the terms that appeared to be statistically 
insignifi cant based on likelihood test ( 2 2-log likelihood ratio) and 
a signifi cance threshold  P value of .05. We also used logistic 
regression to generate a predictive model that estimates the rela-
tive risk (RR) for the different combinations of variables. The out-
come was the presence or absence of COPD defi ned based on 
FEV 1 and FEV 1 /FVC ratio. We included the presence or absence 
of four discrete variables (wheeze, dyspnea, cough, and sputum), 
two continuous variables (age and smoking), and two-way interac-
tions of all variables. We applied the backward elimination strat-
egy to obtain the fi nal predictive model. Every term that had a 
 P  , .1 or had an interaction term with a  P  , .1 was kept in the 
model. This model generated a logit function for calculating the 
RRs (approximations based on ORs) of COPD for combinations 
of symptoms. 
 Figure 1. Long-term smokers with a remote history of lung can-
cer and spirometric evidence of airfl ow obstruction were more 
likely to have received a diagnosis of COPD than long-term smok-
ers with airfl ow obstruction and no history of lung cancer. Dxed  5 
diagnosed; Hx  5 history. 
 Table 3— Number of Symptoms in Long-Term Smokers 
(n  5 2,917) by Pack-Year and FEV 1 
No. Symptoms Pack-y FEV 1 , % Predicted
0 45.1  6 23.5 83.1  6 15.5
1 48.4  6 25.3 77.1  6 17.8
2 51.7  6 28.2 73.1  6 19.0
3 53.5  6 27.5 69.5  6 19.9
4 55.8  6 29.7 62.9  6 21.9
Data are presented as mean  6 SD.
 Table 4— Percentage of Long-Term Smokers (n  5 2,917) 
With Symptoms by FEV 1 
Symptom
FEV 1  . 80% 
Predicted, %







3% of smokers with normal and 4% of smokers with 
restricted spirometry reported having been given a 
diagnosis of asthma. 
 Association of Symptoms With AO 
 On univariate analysis, smoking history, cough, dys-
pnea, sputum, and wheeze all were signifi cantly asso-
ciated with AO ( Table 6 ). Smoking showed the high est 
OR for association with COPD at 3.73 (95% CI, 
3.12-4.45) and was signifi cantly greater than the 
unadjusted OR for any one of the four respiratory 
symptoms evaluated. 
 Sensitivity, Specifi city, Negative and Positive 
Predictive Values, and RRs of Smoking 
History and Respiratory Symptoms 
 Although the absence of symptoms predicted the 
absence of COPD, the presence of symptoms poorly 
predicted the presence of AO in smokers at risk for 
COPD. Sensitivity, specifi city, predictive values and 
with obstruction, 78 never smoked, and the 100 who 
did smoke had a 10.5  6 5.9-pack-year history of 
smoking. 
 Most subjects who reported symptoms had mul-
tiple complaints ( Table 2 ). Among the 3,955 sub-
jects evaluated, 3,261 (83%) reported at least one 
symptom, and 2,579 (65%) reported multiple symp-
toms. This fi nding also was true of the subset of 
long-term smokers (n  5 2,917), where 2,504 (86%) 
reported at least one symptom, and 2,054 (70%) 
reported multiple symptoms. The most common 
combination was cough and sputum production 
either alone or in combination with wheeze or dysp-
nea. Only 13 of 3,261 symptomatic subjects and 10 
of 2,504 symptomatic long-term smokers reported 
sputum without cough; therefore, the complaint of 
sputum in the absence of cough was not analyzed 
further. 
 Underdiagnosis of COPD 
 COPD was underdiagnosed in the entire cohort 
( Fig 2 ) and the subset limited to long-term smokers 
( Fig 3 ). Smokers with spirometric criteria for COPD 
who received medications for or reported a having 
received a diagnosis of COPD tended to have a lower 
percent-predicted FEV 1 ( P  , .001) ( Table 1 ) and 
were more symptomatic than those who had not 
received a diagnosis of or medication for COPD 
( P  , .001) ( Table 2 ). They also were slightly older 
( P  5 .003) and smoked marginally more ( P  , .001) 
than those without COPD ( Table 1 ). Of the 744 long-
term smokers with AO who were neither given a 
diagnosis of nor medicated for COPD, 80% were 
GOLD stage II or greater, and 87% had one or more 
symptoms ( Table 5 ). Conversely, 4% of smokers with 
normal spirometry and 11% with restricted spirome-
try were misclassifi ed as having COPD. Additionally, 
 Table 5— Smokers With Airways Obstruction Not 
Diagnosed as COPD or Asthma (n  5 744) 
Symptom Value
FEV 1 , % predicted 65.3  6 16.3
Pack-y 53.4  6 26.9
Age, y 65.7  6 8.9
FEV 1 50%-80% predicted 466 (63)
FEV 1 30%-50% predicted 117 (16)
FEV 1  , 30% predicted 12 (2)





Data are presented as mean  6 SD or No. (%).
 Figure 2. COPD was frequently underdiagnosed in long-term 
smokers. Dx  5 diagnosis. See Figure 1 legend for expansion of 
the other abbreviation. 
 Figure 3. COPD was missed more frequently in the cohort of 
smokers and nonsmokers than in the subset of long-term smokers 
alone. See Figure 1 legend for expansion of abbreviation. 
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medications, and 36% had not been given a prior 
diagnosis of COPD at admission. 24 
 Data from this study suggest one possible cause for 
the underdiagnosis of COPD, namely confusion with 
asthma. Asthma and COPD share common suscepti-
bility genes, 26,27 common pathophysiologies such as 
bronchial hyperreactivity, 28 and accelerated annual 
decline in FEV 1 , 29,30 and remodeled asthma is a cause 
of COPD. 31 The reported asthma prevalence (12%) 
in our population is signifi cantly higher than Centers 
for Disease Control and Prevention estimates for 
asthma prevalence in men aged  . 35 years (5.5%-
5.8%), 32 which supports the premise that diagnostic 
overlap between asthma and COPD is a cause of 
COPD underdiagnosis. Conversely, 4% of subjects 
with normal and 11% with restricted spirometry were 
misdiagnosed as COPD. 22 The fi xed-ratio defi nition 
of COPD leads to underdiagnosis in younger patients 
and misdiagnosis in the elderly patients. 33 The popu-
lation evaluated in this study showed little difference 
between fi xed-ratio and LLN values for obstruction, 
thus limiting the misdiagnosis rate. 
 This study adds to NHANES in providing preva-
lence and specifi c data on type of respiratory symp-
toms. We show that smokers with AO frequently 
report symptoms that are linked to FEV 1 . The 
frequency of symptoms in smoking populations is 
RRs of specific respiratory symptoms for COPD 
compared with the absence of these symptoms were 
modest ( Tables 7, 8 ). 
 Discussion 
 This study shows that AO is common in long-term 
smokers aged  . 40 years but is infrequently recog-
nized by health-care workers. The prevalence of 
symptoms is high among smokers with AO, but they 
are not sensitive, specifi c, or predictive of AO. There 
is a statistically signifi cant association of both symp-
toms and smoking history with the presence of 
AO. The addition of symptoms to smoking history 
improves diagnostic yield marginally in a complicated 
statistical model but not enough to make them clini-
cally relevant. 
 Our study showed that only 42% of long-term 
smokers with AO were given a diagnosis of COPD, 
confi rming NHANES III data. 2 Others have reported 
underdiagnosis of COPD. 24,25 In a spirometry-based 
screening study of subjects aged  . 40 years, only 
35.1% with AO reported receiving a previous diagno-
sis of chronic bronchitis, emphysema, or COPD. 25 
Similarly, in a study of subjects hospitalized for a 
COPD exacerbation, 56% were receiving respiratory 
 Table 6— Odds Ratios (95% CIs) for Having Airway Obstruction 
Symptom
All Subjects Smokers
Unadjusted Adjusted a Unadjusted Adjusted a 
Cough 1.98 (1.73-2.27) NA b 1.85 (1.58-2.17) NA b 
SOB 1.79 (1.55-2.08) 1.23 (1.03-1.47) 1.91 (1.62-2.26) 1.29 (1.07-1.56)
Sputum 1.95 (1.70-2.34) 1.74 (1.42-2.13) 2.01 (1.73-2.34) 1.63 (1.31-2.04)
Wheeze 2.59 (2.26-2.97) 1.90 (1.61-2.25) 2.28 (1.94-2.66) 1.85 (1.54-2.21)
Smoking c 3.73 (3.12-4.45) 3.59 (2.80-4.61) Adjusted for smoking Adjusted for smoking
NA  5 not applicable; SOB  5 shortness of breath.
 a Adjusted for age, sex, and pack-years smoked in a model including all four symptoms.
 b The odds ratio (OR) for cough depended on the amount of smoking (interaction  P  5 .008), and it followed the formula OR  5 e 0.015  3 pack-years smoked , 
where e  5 2.7183. Therefore, the ORs were 1.35 for 20 pack-years; 1.820 for 40 pack-years, 2.46 for 60 pack-years, 3.32 for 80 pack-years, 4.48 for 
100 pack years, and 6.05 for 120 pack-years.
 c  20 pack-years.
 Table 7— Sensitivity, Specifi city, and Positive and Negative Predictive Values of Symptoms for Airway Obstruction 
Symptom
All Subjects (N  5 3,955) Smokers   20 Pack-y (n  5 2,917)
Sensitivity Specifi city PPV NPV Sensitivity Specifi city PPV NPV
Cough 69 48 43 72 71 44 49 66
Dyspnea 75 37 41 72 76 37 48 67
Sputum 56 60 48 68 57 61 53 65
Wheeze 68 55 47 75 70 49 52 68
  1 symptom 90 22 40 80 92 19 47 75
Smoking   20 pack-y 88 34 43 83 … … … …
NPV  5 negative predictive value; PPV  5 positive predictive value.
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was greater than that for respiratory symptoms, 
which is consistent with other studies where age 
(OR, 2.2-23.8) and smoking status (OR, 2.5-5.8) 
between 66% and 92%, with higher symptom fre-
quencies reported in populations with a lower 
FEV 1 . 34-36 We show that the OR for smoking history 
 Table 8— Relative Risk for Developing COPD Calculated Based on a Logistic Regression Predictive Model 
Variable
Cough  1 Age in Years No Cough  1 Age in Years
40 50 60 70 40 50 60 70
0 pack-y
 No other symptom 1.64 2.23 3.05 4.15 1 1.61 2.58 4.14
 Wheeze 3.13 4.26 5.82 7.92 1.91 3.08 4.93 7.91
 SOB 2.05 2.79 3.81 5.19 1.25 2.01 3.23 5.18
 Cough 1.64 2.23 3.05 4.15 … … … …
 Sputum 2.92 3.97 5.43 7.39 … … … …
 Wheeze  1 SOB 3.92 5.33 7.29 9.92 2.39 3.85 6.17 9.89
 Wheeze  1 sputum 5.57 7.58 10.36 14.09 … … … …
 SOB  1 sputum 3.65 4.96 6.79 9.23 … … … …
 Wheeze  1 SOB  1 sputum 6.96 9.47 12.95 17.61 … … … …
10 pack-y
 No other symptom 1.90 2.59 3.54 4.81 1.07 1.72 2.76 4.43
 Wheeze 3.63 4.94 6.75 9.19 2.04 3.30 5.28 8.46
 SOB 2.38 3.24 4.42 6.02 1.34 2.15 3.46 5.54
 Cough 1.90 2.59 3.54 4.81 … … … …
 Sputum 3.39 4.61 6.30 8.57 … … … …
 Wheeze  1 SOB 4.55 6.18 8.46 11.51 2.56 4.12 6.60 10.58
 Wheeze  1 sputum 6.46 8.79 12.02 16.34 … … … …
 SOB  1 sputum 4.23 5.75 7.88 10.71 … … … …
 Wheeze  1 SOB  1 sputum 8.07 10.99 15.02 20.43 … … … …
20 pack-y
 No other symptom 2.20 2.99 4.09 5.56 1.15 1.85 2.96 4.75
 Wheeze 4.19 5.71 7.80 10.61 2.19 3.53 5.65 9.07
 SOB 2.75 3.74 5.11 6.95 1.43 2.31 3.70 5.94
 Cough 2.20 2.99 4.09 5.56 … … … …
 Sputum 3.91 5.32 7.28 9.90 … … … …
 Wheeze  1 SOB 5.25 7.14 9.77 13.29 2.74 4.42 7.08 11.34
 Wheeze  1 sputum 7.46 10.16 13.88 18.88 … … … …
 SOB  1 sputum 4.89 6.65 9.10 12.37 … … … …
 Wheeze  1 SOB  1 sputum 9.33 12.69 17.35 23.60 … … … …
40 pack-y
 No other symptom 2.95 4.01 5.49 7.47 1.32 2.12 3.39 5.44
 Wheeze 5.63 7.67 10.48 14.26 2.51 4.05 6.48 10.40
 SOB 3.69 5.02 6.86 9.34 1.64 2.64 4.25 6.81
 Cough 2.95 4.01 5.49 7.47 … … … …
 Sputum 5.26 7.15 9.77 13.30 … … … …
 Wheeze  1 SOB 7.06 9.59 13.12 17.86 3.14 5.06 8.11 13.01
 Wheeze  1 sputum 10.03 13.64 18.65 25.36 … … … …
 SOB  1 sputum 6.57 8.93 12.22 16.61 … … … …
 Wheeze  1 SOB  1 sputum 12.53 17.05 23.31 31.70 … … … …
70 pack-y
 No other symptom 4.59 6.24 8.54 11.62 1.61 2.60 4.16 6.68
 Wheeze 8.76 11.93 16.30 22.18 3.08 4.97 7.96 12.77
 SOB 5.74 7.81 10.67 14.53 2.02 3.24 5.21 8.36
 Cough 4.59 6.24 8.54 11.62 … … … …
 Sputum 8.18 11.12 15.20 20.69 … … … …
 Wheeze  1 SOB 10.98 14.92 20.41 27.78 3.86 6.21 9.96 15.96
 Wheeze  1 sputum 15.60 21.22 29.01 39.45 … … … …
 SOB  1 sputum 10.22 13.89 19.01 25.84 … … … …
 Wheeze  1 SOB  1 sputum 19.49 26.52 36.26 49.31 … … … …
Logistic regression predictive model derived from backward elimination (threshold  P  5 .10) of statistical terms that included symptoms, age, pack-
years smoked, and their two-way interactions. The fi nal model was as follows: logit (probability of COPD)  5  2 4.4646  1 0.6463  3 wheeze  1 
0.2223  3 SOB  1 0.4949  3 cough  1 0.5782  3 sputum  1 0.0474  3 age  2 0.0164  3 age  3 cough  1 0.0068  3 pack-years  1 0.0079  3 pack-years  3 cough. 
From this model, we calculated the relative risk (an approximation from the odds ratio) for different combinations as appear in the table. In this 
model, the relative risk for age and pack-years smoked depended on the presence or absence of cough (a refl ection of signifi cant interaction 
between these two variables and cough). See the Table 6 legend for expansion of abbreviation.
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but more likely from failure to follow up the report of 
symptoms with spirometry. Use of COPD symptom 
questionnaires should improve symptom assessment; 
however, in view of the near-universal presence of 
symptoms in persons with AO, the poor sensitivity 
and specifi city of symptoms, the strong predictive 
value of a smoking history of   20 pack-years, and 
emerging data that therapy might modify the course 
of COPD, perhaps a simpler and more effective 
approach would be to screen smokers aged   40 
years and with a history of   20 pack-years smoking 
with spirometry. 
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